Browsing by Subject "Colchicine"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Colchicine in recently hospitalized patients with COVID-19: A randomized controlled trial (COL-COVID)
    (Taylor and Francis Group; Dove Medical Press Limited, 2021-09-11) Pascual-Figal, Domingo A.; Roura-Piloto, Aychel E.; Moral-Escudero, Encarnación; Bernal, Enrique; Albendín-Iglesias, Helena; Pérez-Martínez, M. Teresa; Cebreiros-López, Iria; Hernández-Vicente, Álvaro; Vázquez-Andrés, David; Sánchez-Pérez, Carmen; Khan, Amjad; Sánchez-Cabo, Fátima; García-Vázquez, Elisa; Noguera Velasco, José Antonio; Medicina
    Background: Colchicine has been proposed as a potential therapy in coronavirus disease 2019 (COVID-19) due to their anti-inflammatory actions. Methods: The COL-COVID study was a prospective, randomized, controlled and openlabel clinical trial that compared colchicine added to standard treatment vs standard treatment in hospitalized COVID-19 patients that do not need mechanical ventilatory support. Colchicine was initiated within the first 48 hours of admission at a 1.5 mg loading dose, followed by 0.5 mg b.i.d. for one week and 0.5 mg per day for 28 days. The study endpoints were clinical status (7-points WHO ordinal scale) and inflammatory biomarkers (IL-6 and CRP). Results: A total of 103 patients (51±12 years, 52% male) were randomly allocated to colchicine arm (n=52) and control arm (n=51). At day 28, all patients in the colchicine group were alive and discharged, whereas in the control group, two patients died in-hospital and one patient remained hospitalized. Clinical improvement in terms of changes on WHO scale at day 14 and 28 and time to 1-point clinical improvement did not differ between the two groups. Clinical deterioration (increase of at least 1-point in WHO scale) was observed in a higher proportion of cases in colchicine group (13.8%) vs control group (5.8%) (p=0.303); after adjustment by baseline risk factors and concomitant therapies, colchicine therapy was associated with a lower risk of clinical deterioration (p=0.030). Inflammatory biomarkers CRP and IL-6 concentrations course did not differ between the two arms. Conclusion: In hospitalized COVID-19 patients, colchicine treatment neither improved the clinical status, nor the inflammatory response, over the standard treatment. Nevertheless, a preventive effect for further clinical deterioration might be possible.
  • Thumbnail Image
    Publication
    Open Access
    Morphological changes induced by colchicine in the chick optic cup in early stages of development. A stereological study
    (Murcia : F. Hernández, 1999) Abadía Molina, F.; Calvente, R.; Carmona Martos, R.; Luján, R.; Abadía Fenoll, F.
    In this study chick embryo optic cups at HH stage 13 of development were analyzed under normal conditions and after inoculation with colchicine for 1, 2, 4, and 8 h. Several changes were seen after these periods of treatment: 1) modifications of the structure, with thicker regions in the cup and a general decrease in the total volume according to the duration of exposure to the drug (about 4 times less than normal, 5,035 x lo3 ym3 vs 1,334 x lo3 ym3 after 8 h of treatrnent); 2) enlargement of the ventricular cavity and its closure, due to failure of approximation of retina1 and pigmentary layers; 3) failure of lens development, with delay and impairment of pit formation and deformation of al1 structures; lens volume was less than normal (about 4 times less, 2,148 x 103 pm3 vs 658 x lo3 pm3. after 8 h of treatment); 4) a general segregation of the cells making up the structure, principally in the more active proliferating zones. The local alterations found are described